Granules India Limited (IN:GRANULES)
:GRANULES
Want to see IN:GRANULES full AI Analyst Report?
GRANULES Stock Chart & Stats
₹615.10
₹1.80(0.30%)
At close: 4:00 PM EST
₹615.10
₹1.80(0.30%)
Day’s Range― - ―
52-Week Range₹433.00 - ₹804.05
Previous CloseN/A
Volume528.44K
Average Volume (3M)56.05K
Market Cap
₹193.86B
Enterprise Value₹189.35B
Total Cash (Recent Filing)₹6.26B
Total Debt (Recent Filing)₹18.07B
Price to Earnings (P/E)32.2
Beta0.83
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.24%
Share Statistics
EPS (TTM)21.14
Shares Outstanding247,796,920
10 Day Avg. Volume60,875
30 Day Avg. Volume56,048
Financial Highlights & Ratios
PEG Ratio1.39
Price to Book (P/B)2.97
Price to Sales (P/S)2.81
P/FCF Ratio125.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)32.2
Revenue Forecast (FY)₹62.39B
Bulls Say, Bears Say
Bulls Say
Vertical IntegrationGranules' integrated manufacturing across APIs, PFIs and finished dosage forms creates durable supply security and internal capture of value. This reduces input cost exposure, supports repeat B2B contracts and scale-driven efficiencies that strengthen margins and competitive position over months.
Revenue RecoveryRevenue growth resumed in FY2026 after two flat years, indicating demand resilience and effective commercial execution. A sustained top-line recovery improves capacity utilization, stabilizes operating leverage, and underpins more predictable cash generation over the medium term.
Conservative LeverageDebt-to-equity near 0.39–0.43 is modest for manufacturing, giving the company financial flexibility. A stronger balance sheet lowers refinancing risk, supports ongoing capex and strategic investment, and provides resilience to industry cycles over a 2–6 month horizon.
Bears Say
Margin PressureGross profit falling while revenue rises points to input cost inflation or pricing compression. Persistent margin erosion undermines operating leverage and cash flow generation, limiting the firm’s ability to invest in growth or absorb future cost shocks over the medium term.
Volatile Free Cash FlowInconsistent cash conversion and a ~19% FCF decline in FY2026 signal working-capital or capex demands absorbing earnings. Volatile FCF increases funding uncertainty for dividends, deleveraging, or reinvestment and raises execution risk over the coming quarters.
Declining ROEROE sliding from ~25% to mid-teens indicates reduced capital efficiency and weaker returns on new investments. If sustained, lower ROE suggests structural pressures on profitability and could constrain long-term shareholder value creation and reinvestment returns.
Granules India Limited News
GRANULES FAQ
What was Granules India Limited’s price range in the past 12 months?
Granules India Limited lowest stock price was ₹433.00 and its highest was ₹804.05 in the past 12 months.
What is Granules India Limited’s market cap?
Granules India Limited’s market cap is ₹193.86B.
When is Granules India Limited’s upcoming earnings report date?
Granules India Limited’s upcoming earnings report date is Aug 12, 2026 which is in 53 days.
How were Granules India Limited’s earnings last quarter?
Granules India Limited released its earnings results on Apr 29, 2026. The company reported ₹7.6 earnings per share for the quarter, beating the consensus estimate of ₹6.05 by ₹1.55.
Is Granules India Limited overvalued?
According to Wall Street analysts Granules India Limited’s price is currently Overvalued.
Does Granules India Limited pay dividends?
Granules India Limited pays a Annually dividend of ₹1.75 which represents an annual dividend yield of 0.24%. See more information on Granules India Limited dividends here
What is Granules India Limited’s EPS estimate?
Granules India Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Granules India Limited have?
Granules India Limited has 247,796,920 shares outstanding.
What happened to Granules India Limited’s price movement after its last earnings report?
Granules India Limited reported an EPS of ₹7.6 in its last earnings report, beating expectations of ₹6.05. Following the earnings report the stock price went up 0.078%.
Which hedge fund is a major shareholder of Granules India Limited?
Currently, no hedge funds are holding shares in IN:GRANULES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Granules India Limited
Founded in 1984 and headquartered in Hyderabad, India, Granules India Limited operates as a key player in the pharmaceutical sector. The company is engaged in the manufacturing and global distribution of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs), intermediate compounds for drug formulation, and final dosage forms (FDFs). Its API portfolio addresses various therapeutic categories, such as antiviral medications, treatments for hypertension, antihistamines, anti-infectives, pain relief agents, anticoagulants, anti-fibrinolytic drugs, and platelet inhibitors. Additionally, Granules produces a variety of FDFs, encompassing tablets, caplets, and press-fit capsules, which are supplied in bulk, blister packs, and bottles. The firm also develops specialized products for oncology. Granules India Limited maintains a broad international presence, with its products reaching markets across India, North America, Europe, Latin America, Africa, and the Middle East.
Technical Analysis
Alembic Pharmaceuticals Limited
―
Aurobindo Pharma Ltd
―
Cipla Ltd
―
Glenmark Pharmaceuticals Limited
―
Sanofi India Limited
―